# Year 7 Administrative Supplement to INSPPIRE 2

> **NIH NIH U01** · UNIVERSITY OF IOWA · 2021 · $773,695

## Abstract

PROJECT SUMMARY
Acute pancreatitis (AP) is increasingly recognized in children, with an incidence approaching
that of adults. Most children with pancreatitis have a single, mild, acute episode that resolves
without complications. However, a subset of children with AP develops recurrent episodes
(defined as acute recurrent pancreatitis or ARP) and some progress to chronic pancreatitis
(CP). Pediatric ARP and CP significantly impact quality of life and carry high healthcare costs.
Few studies have been performed to characterize the natural history pediatric ARP and CP, to
identify its risk factors and to determine predictors of disease course. As INSPPIRE
(INternational Study Group of Pediatric Pancreatitis: In search for a cuRE), the first multicenter,
multidisciplinary collaboration in pediatric pancreatitis, we determined that children with ARP
harbor multiple genetic risk variants and rapidly transition to CP, exocrine pancreatic
insufficiency (EPI) and diabetes mellitus (DM). The risk factors that predispose children to
early onset pancreatitis, rapid progression to CP and premature loss of exocrine and
endocrine function are not well-known. The objective of this application is to delineate the
natural history of pediatric CP through careful prospective analysis of INSPPIRE 2 cohort, to
define the impact of genetic modifiers on disease course and to determine the mechanisms
involved in pancreatogenic diabetes mellitus (T3cDM). The overall hypothesis is that genetic
factors predispose children to early onset CP, EPI, and DM. Our specific aims are: 1)
Characterize pediatric CP, determine predictors of disease onset and progression; 2) Determine
the impact of genetic variants on disease onset and progression; 3) Identify mechanisms
underlying disturbed glucose regulation in pediatric ARP and CP. This project will provide
insight into the pathophysiology of pediatric pancreatitis, investigate the impact of genetic
variants on disease course and explore the mechanisms of early islet cell dysfunction in
pediatric ARP and CP. Our long-term goal is to develop diagnostic modalities, prognostic factors
and innovative treatment approaches for pediatric ARP and CP.

## Key facts

- **NIH application ID:** 10469779
- **Project number:** 3U01DK108334-07S1
- **Recipient organization:** UNIVERSITY OF IOWA
- **Principal Investigator:** MARK E. LOWE
- **Activity code:** U01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $773,695
- **Award type:** 3
- **Project period:** 2021-07-01 → 2022-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10469779

## Citation

> US National Institutes of Health, RePORTER application 10469779, Year 7 Administrative Supplement to INSPPIRE 2 (3U01DK108334-07S1). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10469779. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*